Mednax Inc. (MD) Given Average Recommendation of “Hold” by Analysts
Mednax Inc. (NYSE:MD) has earned an average recommendation of “Hold” from the eleven analysts that are currently covering the company. Six investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $73.75.
Several research analysts have weighed in on the stock. Mizuho lowered shares of Mednax from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $69.00 to $64.00 in a research note on Wednesday, November 9th. Raymond James Financial Inc. lowered shares of Mednax from an “outperform” rating to a “market perform” rating in a research note on Thursday, October 27th. Zacks Investment Research raised shares of Mednax from a “sell” rating to a “hold” rating in a research note on Thursday, October 27th. Jefferies Group lowered their target price on shares of Mednax from $80.00 to $75.00 and set a “buy” rating for the company in a research note on Friday, August 26th. Finally, Citigroup Inc. lowered their target price on shares of Mednax from $76.00 to $72.00 and set a “neutral” rating for the company in a research note on Wednesday, August 17th.
In related news, Director Md Pascal J. Goldschmidt sold 1,500 shares of the firm’s stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $65.01, for a total value of $97,515.00. Following the sale, the director now owns 12,755 shares of the company’s stock, valued at $829,202.55. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 2.40% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD boosted its stake in Mednax by 6.8% in the third quarter. Price T Rowe Associates Inc. MD now owns 8,034,055 shares of the company’s stock worth $532,256,000 after buying an additional 508,260 shares during the last quarter. Vanguard Group Inc. boosted its stake in Mednax by 0.6% in the second quarter. Vanguard Group Inc. now owns 6,873,895 shares of the company’s stock worth $497,877,000 after buying an additional 38,874 shares during the last quarter. William Blair Investment Management LLC boosted its stake in Mednax by 5.9% in the second quarter. William Blair Investment Management LLC now owns 5,061,763 shares of the company’s stock worth $366,623,000 after buying an additional 283,674 shares during the last quarter. BlackRock Fund Advisors boosted its stake in Mednax by 2.4% in the third quarter. BlackRock Fund Advisors now owns 3,664,544 shares of the company’s stock worth $242,776,000 after buying an additional 86,578 shares during the last quarter. Finally, Nordea Investment Management AB boosted its stake in Mednax by 2.1% in the third quarter. Nordea Investment Management AB now owns 2,878,350 shares of the company’s stock worth $190,691,000 after buying an additional 60,410 shares during the last quarter. 98.45% of the stock is currently owned by institutional investors.
Mednax (NYSE:MD) traded down 0.08% during mid-day trading on Wednesday, hitting $65.96. 151,467 shares of the stock traded hands. The stock has a market cap of $6.11 billion, a PE ratio of 18.12 and a beta of 0.62. Mednax has a 12-month low of $59.36 and a 12-month high of $76.96. The company has a 50 day moving average of $63.96 and a 200-day moving average of $67.35.
Mednax (NYSE:MD) last announced its earnings results on Thursday, October 27th. The company reported $1.09 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.11 by $0.02. The company had revenue of $828 million for the quarter, compared to analysts’ expectations of $821.18 million. Mednax had a return on equity of 14.47% and a net margin of 10.97%. The company’s quarterly revenue was up 14.6% compared to the same quarter last year. During the same period last year, the business earned $1.10 EPS. Equities research analysts forecast that Mednax will post $4.04 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2016/11/30/mednax-inc-md-given-average-recommendation-of-hold-by-analysts.html.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. The Company’s national network consists of approximately 3,240 affiliated physicians, including approximately 1,100 physicians who provide neonatal clinical care, in over 30 states and Puerto Rico, within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Stock Ratings for Mednax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc. and related stocks with our FREE daily email newsletter.